Skip to content
Veracyte is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company’s products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary.
Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a $2 billion market opportunity. Veracyte is based in South San Francisco, California. Veracyte’s common stock is listed on The NASDAQ Global Market under the symbol VCYT.


Press Releases

Date Title and Summary Additional Formats
Toggle Summary Veracyte to Host Conference Call and Webcast to Discuss Third Quarter 2018 Financial Results on Monday, October 29, 2018
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 15, 2018-- Veracyte, Inc. (Nasdaq: VCYT) will release its third quarter 2018 financial results after the close of market on Monday, October 29, 2018 . Company management will host a conference call and webcast to discuss financial results and
Toggle Summary Veracyte Announces Presentation of “Real World” Clinical Utility Data at CHEST 2018 Showing Percepta Classifier Reduces Invasive Procedures in Lung Cancer Diagnosis
Preliminary data from ongoing, three-year registry study demonstrate that reduction in potentially harmful invasive procedures extends for first 12 months post-test SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Oct. 9, 2018-- Veracyte, Inc. (Nasdaq: VCYT) announced that new interim data from a


Date Event Details
Summary Toggle Oct 29, 2018 1:30 PM PDT
Veracyte Third Quarter 2018 Financial Results Webcast
Summary Toggle Oct 2, 2018 1:05 PM EDT
Cantor 2018 Global Healthcare Conference – Webcast and Presentation


Bonnie H. Anderson
Chairman of the Board and Chief Executive Officer


Title Documents

Cantor 2018 Global Healthcare Conference